Forus Health Private Limited

16/02/2026

We’re proud to share that Forus Health has been selected as one of the Top 20 global finalists for the AI for ALL Global Impact Challenge at the India AI Impact Summit 2026.

Selected from over 4,650 applications spanning 60+ countries, our AI-powered retinal screening platform — designed to analyze retinal images and prioritize high-risk cases for timely clinical intervention, enabling cost-effective deployment at scale — stands alongside leading global solutions delivering scalable, real-world impact.

This milestone reflects the strength of our clinical partnerships and the discipline of the teams driving implementation at scale.

Join us at the Summit in New Delhi as we present and connect with innovators, health leaders, and partners shaping responsible AI in healthcare.

Click to read more - https://bit.ly/4tBgxfO

Venkatakrishnan S Midhula Vijayan, PhD Subhajit Banerjee Purnapatra Karan Rohera

11/02/2026

Retinal screening in neonatal and pediatric care, particularly for Retinopathy of Prematurity (ROP), requires clarity, speed, and consistency, especially when early retinal changes may not be externally visible.

Dr. Ahmed Habib, Vitreo Retinal Professor at Al Mashreq Eye Centre, Egypt, highlights the importance of dependable imaging systems that support early and accurate diagnosis.

3nethra neo captures 120° wide-field retinal images, and its portability and intuitive interface allow efficient integration into routine clinical workflows, supporting timely evaluations without compromising image quality.

With over 600 installations across 6 continents, 3nethra neo continues to demonstrate global clinical adoption and sustained trust across healthcare institutions.

Reach out at askus@forushealth.com to learn more.

Donny Thomas Manish Vora Varun Dhawan

04/02/2026

We are proud to partner with L V PRASAD EYE INSTITUTE (LVPEI) to bring two clinically validated eye-care technologies—BaViS (Baby Vision Screener) and PupilN (Portable Automated Pupilometer) to market.

Developed at LVPEI’s Centre for Technology Innovation (CFTI), both solutions are now market-ready following years of close collaboration between clinicians and engineers. Through this partnership, we will lead production and commercialization, enabling wider access to reliable tools for early vision screening and diagnostic support.

We thank the clinicians, engineers, and the entire CFTI team—past and present. This collaboration reflects a shared commitment to science-led innovation, early detection, and scalable eye-care solutions—designed for real-world clinical impact.

Chandrasekhar K Ramesh Kekunnaya, MD, FRCS

03/02/2026

We are proud to share that FH-POISE™ for Diabetic Retinopathy has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO). This milestone reflects the rigorous engineering, clinical validation, and quality standards applied during development and marks a key step toward regulated, large-scale deployment in screening programs.

The development emphasized extensive real-world validation across large, diverse datasets and varied clinical settings, prioritizing reliability over speed—so it performs consistently at scale where it matters most.

Meaningful healthcare technology is defined not by speed to market, but by reliability, readiness, and proven performance in real-world clinical use, enabling clinicians to detect diabetic retinopathy earlier, screen
more patients efficiently and improve outcomes at scale.

We thank our regulatory, quality, engineering, and clinical teams for their relentless efforts in making this milestone possible.

Chandrasekhar K KMK Rajendran Dr. Sreedhar Reddy M.S Subhajit Banerjee Purnapatra Dr. Deepthi K Prasad, PhD Sourav Kumar Patnaik Amrutha Kp Midhula Vijayan, PhD

01/02/2026

At a recent panel on MedTech & Medical Equipment: Bringing Scale by VCCircle, our Founder & CEO Chandrasekhar K discussed how AI-enabled diagnostics and indigenous innovation are reshaping India’s medtech growth story.

From early screening to population-scale deployment, technology will define the next decade of healthcare impact.

30/01/2026

Retinopathy of prematurity (ROP) can progress rapidly in preterm infants, often without any visible external signs. Early retinal evaluation is therefore critical in neonatal care.

Dr. Mahesh Uparkar, an ophthalmologist at Prism Eye Institute & Research Centre, highlights his experience using 3nethra neo for ROP screening in NICUs. This advanced system captures 120° wide-field retinal images at the bedside, allowing clinicians to detect subtle retinal changes early—without moving the infant from the unit.

With over 600 installations across six continents, 3nethra neo is now a cornerstone of structured ROP screening programs in neonatal care centers worldwide.

Reach out at askus@forushealth.com to learn more.

Donny Thomas Manish Vora Varun Dhawan

28/01/2026

At APAO 2026 in Hong Kong, we will showcase our advanced eye-care solutions: the 3nethra neo HD FA, offering digital ultra-widefield retinal imaging with Fluorescein Angiography, and the 3nethra specto, a smartphone-enabled wearable refractor designed for portable vision testing.

We look forward to showcasing technologies that have reimagined how eye care is delivered.

Reach out at askus@forushealth.com to learn more.

Manish Vora

27/01/2026

We are featured in Gulf News showcasing how innovation in eye care is helping improve screening and clinical outcomes.

By combining portable imaging with AI-enabled solutions, we continue to focus on building technology that integrates seamlessly into everyday clinical workflows and supports better patient care across the globe.

Chandrasekhar K

Read the full article - https://bit.ly/3NGdin2

From rural access to early detection, these ventures are redefining healthcare standards

26/01/2026

Happy Republic Day.

As India moves forward, we remain focused on building Made in India medical technology for real-world clinical settings, enabling better screening, earlier detection, and improved patient outcomes.

23/01/2026

In this feature, our Chief Manufacturing and Regulatory Officer, R J Venkataraman, shares how manufacturing and regulatory decisions are translated into devices used in routine clinical practice across diverse care settings.

22/01/2026

3nethra neo HD FA is an ultra wide-field digital retinal imaging system with Fluorescein Angiography capability, used for retinal imaging and evaluation, including retinopathy of prematurity (ROP).

It captures high-resolution retinal images up to 150° using a 20-megapixel camera sensor, enabling clear imaging of retinal blood vessels and the peripheral retina, which is critical for assessing retinal development in preterm infants.

With a compact and ergonomic design, intelligent controls, historical data storage, AI-enabled analysis, and telemedicine compatibility, the system is used for retinal image capture, review, comparison over time, and remote assessment.

Reach out at askus@forushealth.com for more details.

Donny Thomas Manish Vora

21/01/2026

Forus Health at APAO 2026 | Hong Kong

Forus Health will be part of APAO 2026 in Hong Kong, showcasing 3nethra neo HD FA, a digital ultra wide-field retinal imaging system with fluorescein angiography, and 3nethra specto, a smartphone enabled wearable subjective refractor designed for portable vision testing.

We look forward to showcasing technologies that have reimagined how eye care is delivered.

Reach out at askus@forushealth.com to learn more.

Manish Vora